Amgen (AMGN) Asset Writedowns and Impairment (2022 - 2025)

Amgen (AMGN) has reported Asset Writedowns and Impairment for 4 consecutive years, with $400.0 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Asset Writedowns and Impairment rose 555.74% year-over-year to $400.0 million; the TTM figure through Mar 2026 stood at $400.0 million (down 55.11% YoY), while the FY2025 annual figure was $1.2 billion, up 654.72% from the prior year.
• Asset Writedowns and Impairment came in at $400.0 million for Q3 2025 at Amgen, down from $800.0 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $851.0 million in Q4 2023, with the low at $2.0 million in Q4 2022.
• Average Asset Writedowns and Impairment over 4 years is $277.1 million, with a median of $64.5 million recorded in 2024.
• Across the five-year window, Asset Writedowns and Impairment surged 42450.0% in 2023 and plunged 96.47% in 2024, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $2.0 million in 2022, then soared by 42450.0% to $851.0 million in 2023, then slumped by 96.47% to $30.0 million in 2024, then jumped by 1233.33% to $400.0 million in 2025.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $400.0 million, $800.0 million, and $30.0 million for Q3 2025, Q1 2025, and Q4 2024 respectively.